相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
Gabriela S. Hobbs et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
Nicolaus Kroeger et al.
BLOOD (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
N. M. Kroeger et al.
LEUKEMIA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Fabio P. S. Santos et al.
Anti-Cancer Agents in Medicinal Chemistry (2012)
The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
Umberto Gianelli et al.
MODERN PATHOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
Ruben A. Mesa et al.
LEUKEMIA RESEARCH (2009)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
分享论文
